MX2009010167A - Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph. - Google Patents

Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.

Info

Publication number
MX2009010167A
MX2009010167A MX2009010167A MX2009010167A MX2009010167A MX 2009010167 A MX2009010167 A MX 2009010167A MX 2009010167 A MX2009010167 A MX 2009010167A MX 2009010167 A MX2009010167 A MX 2009010167A MX 2009010167 A MX2009010167 A MX 2009010167A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
control agent
solid pharmaceutical
benzimidazole
carboxylate derivative
Prior art date
Application number
MX2009010167A
Other languages
English (en)
Inventor
Shuji Yoneyama
Yutaka Tanoue
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009010167A publication Critical patent/MX2009010167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee una composición farmacéutica sólida que contiene el compuesto (I) el cual ejerce una acción antagonista del receptor de angiotensina II y un agente para el control del pH, la composición es superior en términos de la estabilidad y propiedad de disolución al compuesto (I).
MX2009010167A 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph. MX2009010167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90851507P 2007-03-28 2007-03-28
PCT/JP2008/056522 WO2008123536A1 (en) 2007-03-28 2008-03-26 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent

Publications (1)

Publication Number Publication Date
MX2009010167A true MX2009010167A (es) 2009-10-12

Family

ID=39590787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010167A MX2009010167A (es) 2007-03-28 2008-03-26 Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.

Country Status (19)

Country Link
US (1) US9066936B2 (es)
EP (1) EP2124903B1 (es)
JP (1) JP5283632B2 (es)
KR (1) KR20090125846A (es)
CN (1) CN101677961B (es)
AR (1) AR065850A1 (es)
AU (1) AU2008235790B2 (es)
BR (1) BRPI0809522A2 (es)
CA (1) CA2681143C (es)
CL (1) CL2008000868A1 (es)
EA (1) EA016593B1 (es)
ES (1) ES2743784T3 (es)
IL (1) IL201188A0 (es)
MX (1) MX2009010167A (es)
NZ (1) NZ579851A (es)
PE (2) PE20130210A1 (es)
PT (1) PT2124903T (es)
TW (1) TWI415634B (es)
WO (1) WO2008123536A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590948A (en) 2008-07-31 2012-06-29 Takeda Pharmaceutical Solid pharmaceutical composition comprising a diuretic, ph control agent and an oxadiazole
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
KR20140030237A (ko) * 2011-05-23 2014-03-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤즈이미다졸 유도체를 함유하는 고체 약제학적 조성물
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
TWI536992B (zh) 2012-09-19 2016-06-11 Taiho Pharmaceutical Co Ltd And a medicinal composition for oral administration of improved elution and / or absorption
EP2928468A4 (en) 2012-12-05 2016-07-27 Sawai Seiyaku Kk PREPARATION CONTAINING CANDÉSARTAN CILEXÉTIL
WO2014102628A1 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Stable pharmaceutical composition comprising azilsartan medoxomil
EP2952187A4 (en) 2013-01-30 2016-08-17 Sawai Seiyaku Kk PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
IN202021028444A (es) * 2020-07-03 2022-01-28
CN117122570B (zh) * 2022-05-19 2024-04-09 北京阳光诺和药物研究股份有限公司 一种提高稳定性的美阿沙坦钾片及其制备方法
WO2024109927A1 (zh) * 2022-11-24 2024-05-30 上海云晟研新生物科技有限公司 包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
JP3810020B2 (ja) * 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
CA2577233C (en) * 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
AU2573800A (en) * 1999-02-19 2000-09-04 Takeda Chemical Industries Ltd. Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
NZ514855A (en) * 1999-04-28 2004-01-30 Takeda Chemical Industries Ltd Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
EP1258254A4 (en) * 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
JP2001316296A (ja) * 2000-02-21 2001-11-13 Takeda Chem Ind Ltd 水に難溶性の生理活性化合物の徐放性製剤、その製造法および用途
WO2003041739A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
CA2511737A1 (en) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
CA2519211A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2005117591A2 (en) * 2004-05-28 2005-12-15 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
TW200740752A (en) 2005-05-13 2007-11-01 Microbia Inc 4-Biarylyl-1-phenylazetidin-2-ones
KR20130135994A (ko) 2005-06-27 2013-12-11 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
ES2743784T3 (es) 2020-02-20
TWI415634B (zh) 2013-11-21
NZ579851A (en) 2012-02-24
PE20130210A1 (es) 2013-03-11
PE20090550A1 (es) 2009-06-01
EA200970896A1 (ru) 2010-04-30
CL2008000868A1 (es) 2008-10-10
AU2008235790B2 (en) 2013-06-06
KR20090125846A (ko) 2009-12-07
EP2124903A1 (en) 2009-12-02
AU2008235790A1 (en) 2008-10-16
CA2681143C (en) 2017-01-03
CA2681143A1 (en) 2008-10-16
BRPI0809522A2 (pt) 2014-10-14
JP5283632B2 (ja) 2013-09-04
IL201188A0 (en) 2010-05-17
AR065850A1 (es) 2009-07-08
CN101677961B (zh) 2012-10-17
CN101677961A (zh) 2010-03-24
JP2010522692A (ja) 2010-07-08
EP2124903B1 (en) 2019-06-12
US20100121071A1 (en) 2010-05-13
WO2008123536A1 (en) 2008-10-16
TW200902089A (en) 2009-01-16
PT2124903T (pt) 2019-09-26
US9066936B2 (en) 2015-06-30
EA016593B1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
MX2009010167A (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.
HUS1800010I1 (hu) 4-Fenil-6-(2,2,2-trifluor-1-feniletoxi)pirimidin-alapú vegyületek és alkalmazási eljárásaik
TW200740459A (en) Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
IL197933A (en) Knaase inhibitors, pharmaceuticals containing them and their uses
MY148634A (en) Pyridazinone derivatives
EA201170483A1 (ru) Твердая фармацевтическая композиция
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine
UA84318C2 (ru) Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
UA85593C2 (uk) Похідні хіназолінону як інгібітори parp
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
ATE469895T1 (de) Cgrp-rezeptorantagonisten
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
WO2009042114A3 (en) Phenazine derivatives and uses thereof
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
MX2010001574A (es) Ligandos del receptor cannabinoide.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
MX2010004852A (es) Combinacion antihelmintica.
WO2007095113A3 (en) Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan

Legal Events

Date Code Title Description
FG Grant or registration